Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models
Open Access
- 31 January 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , srep41809
Abstract
Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HPßCD and tested in animal models of human and syngeneic GBM. Administration of a single IV dose resulted in 7-fold higher levels of HET0016 in plasma and 3.6-fold higher levels in tumor at 60 min than that in IP route. IV treatment with HPßCD-HET0016 decreased tumor growth, and altered vascular kinetics in early and late treatment groups (p < 0.05). Similar growth inhibition was observed in syngeneic GL261 GBM (p < 0.05). Survival studies using patient derived xenografts of GBM811, showed prolonged survival to 26 weeks in animals treated with focal radiation, in combination with HET0016 and TMZ (p < 0.05). We observed reduced expression of markers of cell proliferation (Ki-67), decreased neovascularization (laminin and αSMA), in addition to inflammation and angiogenesis markers in the treatment group (p < 0.05). Our results indicate that HPßCD-HET0016 is effective in inhibiting tumor growth through decreasing proliferation, and neovascularization. Furthermore, HPßCD-HET0016 significantly prolonged survival in PDX GBM811 model.Keywords
This publication has 50 references indexed in Scilit:
- Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivoChinese Journal of Cancer, 2014
- Development of a novel animal model to differentiate radiation necrosis from tumor recurrenceJournal of Neuro-Oncology, 2012
- Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2010
- Cytochrome P450-derived eicosanoids: the neglected pathway in cancerCancer and Metastasis Reviews, 2010
- Changes in Vascular Permeability and Expression of Different Angiogenic Factors Following Anti-Angiogenic Treatment in Rat GliomaPLOS ONE, 2010
- Gliosarcoma Stem Cells Undergo Glial and Mesenchymal Differentiation In VivoStem Cells, 2009
- Intravenous Formulation of N-Hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for Inhibition of Rat Brain 20-Hydroxyeicosatetraenoic Acid FormationDrug Metabolism and Disposition, 2008
- Monocyte Chemotactic Protein (MCP)-1 Promotes Angiogenesis via a Novel Transcription Factor, MCP-1-induced Protein (MCPIP)Journal of Biological Chemistry, 2008
- Epoxyeicosatrienoic acids, cell signaling and angiogenesisProstaglandins & Other Lipid Mediators, 2007
- O6‐alkylguanine‐DNA alkyltransferase: Role in carcinogenesis and chemotherapyBioEssays, 2002